HONG KONG, Feb. 12, 2025 /PRNewswire/ -- Akeso, Inc. (9926. HK) ("Akeso" or the "Company") announced the recent completion of the first patient enrollment in the Phase 3 randomized, double-blind, multicenter clinical trial (COMPASSION-30/AK104-309) for its independently developed...
Hence then, the article about akeso announced enrollment of first patient in phase 3 trial of cadonilimab for consolidation therapy after concurrent or sequential chemoradiotherapy in nsclc was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Akeso Announced Enrollment of First Patient in Phase 3 Trial of Cadonilimab for Consolidation Therapy After Concurrent or Sequential Chemoradiotherapy in NSCLC )
Also on site :
- Neon Sets ‘Artificial’ Oscar Campaign With Andrew Garfield in Supporting Actor, Yura Borisov in Lead (EXCLUSIVE)
- ‘Artificial’ First Reactions: Luca Guadagnino’s OpenAI Drama is ‘Provocative,’ ‘Downright Horrifying’ and His ‘Best Film in a Decade’
- ‘Artificial’ Review: Luca Gaudagnino Has Made the Real Sequel to ‘The Social Network’ — a Brain-Spinning Tech-Geek Docudrama, Brilliantly Acted by Andrew Garfield and Yura Borisov